Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

ASP2390

Phase 1Biologic

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

AllergicActive, not recruiting

AllergicPhase 1

Active, not recruiting

Timeline

Expected Milestones

Q4 2026

Phase 1Active, not recruiting

Allergic

NCT04184895

Clinical

Trials by Indication[1]

Allergic1 trial

A Phase 1 Multiple Ascending Intradermal Dose Study to Assess the Safety, Tolerability and Immunological Response of ASP2390 in Adult Subjects Allergic to House Dust Mites

Active, not recruiting· Astellas logo

Astellas·Phase 1·NCT04184895·28 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ASP2390. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ASP2390 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ASP2390. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Astellas company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: Astellas

Related News